MG
REGN icon

Marex Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Marex Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,000
Closed -$23.2M – 1225
2025
Q4 		$23.2M Sell
30,000
-20,000
-40% -$13.6M 0.15% 114
2025
Q3 		$28.1M Hold
50,000
– – 0.2% 99
2025
Q2 		$26.3M Buy
+50,000
New +$27.9M 0.23% 86

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Marex Group's REGN Position: Q1 2026 in Review

Marex Group reduced its Regeneron Pharmaceuticals (REGN) stake by 94% in Q1 2026, selling an estimated $22.5M and leaving 1,739 shares worth $1.34M. The position accounts for 0.01% of the portfolio, ranked #382.

Marex Group first reported a position in REGN in Q4 2022 and has held it in 9 quarters since. The position peaked at $50.1M in Q4 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Marex Group held 1,739 shares of Regeneron Pharmaceuticals worth $1.34M as of Q1 2026.
  • Marex Group sold 29,450 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $22.5M.
  • Regeneron Pharmaceuticals made up 0.01% of Marex Group's portfolio in Q1 2026, its #382 holding.
  • Marex Group first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 9 quarters since.
  • Marex Group's Regeneron Pharmaceuticals position peaked at $50.1M in Q4 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.